These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7325636)

  • 1. Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus.
    Moorman DR; Mandell GL
    Antimicrob Agents Chemother; 1981 Dec; 20(6):709-13. PubMed ID: 7325636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant Staphylococcus aureus strains selected in vitro.
    Wang C; Fang R; Zhou B; Tian X; Zhang X; Zheng X; Zhang S; Dong G; Cao J; Zhou T
    BMC Microbiol; 2019 Sep; 19(1):220. PubMed ID: 31533633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin.
    Burnie J; Matthews R; Jiman-Fatami A; Gottardello P; Hodgetts S; D'arcy S
    Clin Infect Dis; 2000 Sep; 31(3):684-9. PubMed ID: 11017816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.
    Rothstein DM; Farquhar RS; Sirokman K; Sondergaard KL; Hazlett C; Doye AA; Gwathmey JK; Mullin S; van Duzer J; Murphy CK
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3658-64. PubMed ID: 16940074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.
    Fujii K; Tsuji A; Miyazaki S; Yamaguchi K; Goto S
    Antimicrob Agents Chemother; 1994 May; 38(5):1118-22. PubMed ID: 8067748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tentative inhibition zone criteria (Bauer-Kirby agar disk diffusion method) for rifampin against staphylococci.
    Traub WH; Spohr M; Bauer D
    Chemotherapy; 1987; 33(6):412-8. PubMed ID: 3428008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus.
    Bayer AS; Morrison JO
    Antimicrob Agents Chemother; 1984 Aug; 26(2):220-3. PubMed ID: 6567464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination.
    Standiford HC; Walsh TJ; Drusano GL; Tatem BA; Townsend RJ
    Diagn Microbiol Infect Dis; 1993; 17(2):135-42. PubMed ID: 8243034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus.
    Maduri Traczewski M; Goldmann DA; Murphy P
    Antimicrob Agents Chemother; 1983 Apr; 23(4):571-6. PubMed ID: 6859835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular surveillance of putative virulence factors and antibiotic resistance in Staphylococcus aureus isolates recovered from intra-mammary infections of river buffaloes.
    Kumar R; Yadav BR; Anand SK; Singh RS
    Microb Pathog; 2011; 51(1-2):31-8. PubMed ID: 21440053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different distribution of antimicrobial resistance genes and virulence profiles of Staphylococcus aureus strains isolated from clinical mastitis in six countries.
    Monistero V; Barberio A; Biscarini F; Cremonesi P; Castiglioni B; Graber HU; Bottini E; Ceballos-Marquez A; Kroemker V; Petzer IM; Pollera C; Santisteban C; Veiga Dos Santos M; Bronzo V; Piccinini R; Re G; Cocchi M; Moroni P
    J Dairy Sci; 2020 Apr; 103(4):3431-3446. PubMed ID: 32008788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraosteoblastic activity of levofloxacin and rifampin alone and in combination against clinical isolates of meticillin-susceptible Staphylococcus aureus causing prosthetic joint infection.
    Meléndez-Carmona MÁ; Muñoz-Gallego I; Viedma E; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2019 Sep; 54(3):356-360. PubMed ID: 31254616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization.
    Peterson LR; Quick JN; Jensen B; Homann S; Johnson S; Tenquist J; Shanholtzer C; Petzel RA; Sinn L; Gerding DN
    Arch Intern Med; 1990 Oct; 150(10):2151-5. PubMed ID: 2222100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Bahl D; Miller DA; Leviton I; Gialanella P; Wolin MJ; Liu W; Perkins R; Miller MH
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1293-7. PubMed ID: 9174186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on multi-antibiotic resistant strains of Staphylococcus aureus.
    Chmel H; Person A; Tecson-Tumang F
    Infection; 1982; 10(3):173-6. PubMed ID: 6980839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes.
    Mandell GL
    Rev Infect Dis; 1983; 5 Suppl 3():S463-7. PubMed ID: 6356278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.
    Hackbarth CJ; Chambers HF; Sande MA
    Antimicrob Agents Chemother; 1986 Apr; 29(4):611-3. PubMed ID: 3707110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
    Chojnacki M; Philbrick A; Wucher B; Reed JN; Tomaras A; Dunman PM; Wozniak RAF
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30420484
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of eleven antimicrobial agents against methicillin-, methicillin- and rifampin-resistant Staphylococcus aureus.
    Chokkavelu V; Chandrasekar P; Rolston K; LeFrock JL; Schell RF
    Chemotherapy; 1984; 30(2):97-101. PubMed ID: 6559665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.